title: Clinical study on mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer.
abstract: OBJECTIVE
  To investigate short-term response rate, quality of life and toxicities of mannan peptide combined with TP regimen in treating patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Forty one patients with NSCLC were divided into an experimental group treated with TP regimen combined with mannan peptide (21 patients) and a control group treated with TP alone (20 patients).
  
  
  RESULTS
  Response rates were 61.9% (13/21) for the experimental and 60% (12/20) for the control group (p>0.05). Regarding toxicity, white blood cell decreased more frequently in the control group (65%, 13/20) than in the experimental group (33.3%, 7/21) (p<0.05); nausea and vomiting also occurred more frequently in the control group (55%, 11/20 vs 23.8%, 5/21) (p<0.05). In terms of quality of life, this index was improved by 57.1% (12/21) and 25% (5/20) in experimental and control groups, respectively (p<0.05).
  
  
  CONCLUSIONS
  Response rate of TP after combined with mannan peptide is mildly increased, while this combination alleviates bone marrow suppression as well as nausea and vomiting of TP, and improves quality of life when treating patients with NSCLC. However, this conclusion should be confirmed by randomized clinical trails.
authors.affiliation: Tumor Department of Siyang People's Hospital, Suqian, China E-mail : huangxinen06@aliyun.com.
authors.forename: Huai-An
authors.initials: HA
authors.lastname: Yan
authors.forename: Kang
authors.initials: K
authors.lastname: Shen
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D016022:Case-Control Studies; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006020:Glycopeptides / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel; D011379:Prognosis; D011788:Quality of Life; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D006020:Glycopeptides; D008351:Mannans; D043823:Taxoids; D017239:Paclitaxel; D002945:Cisplatin